Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease (Fierce Healthcare)

Flagship Pioneering has launched a new biotech startup, Etiome, with $50 million in funding and a bold vision to preempt disease before serious symptoms arise. Combining multiomics, AI, and EHR data, Etiome builds “molecular movies” that map how diseases evolve—starting with fatty liver disease (MASH)—to identify when and how to intervene with targeted therapies. By catching disease progression at earlier stages, Etiome aims to usher in a new era of preemptive medicine for conditions like neurodegeneration, cancer, and autoimmune disorders.